
Loading, please wait...

Loading, please wait...

The management of uncontrolled bleeding remains a significant clinical hurdle, particularly for patients receiving anticoagulant therapy. Recently, researchers developed a novel gelatin sponge patch that integrates PANS coating to provide superior hemostatic sponge adhesion independently of the classical coagulation cascade. This dual-function design addresses the critical need for effective sealing in unsuturable visceral injuries and heparinized subjects.
Specifically, the sponge employs a one-sided coating of N-hydroxysuccinimide (NHS) ester-functionalized poly (acrylic acid-co-N-succinimidyl acrylate), known as PANS. This polymer facilitates the formation of covalent and hydrogen bonding cross-links between the material and blood proteins. Consequently, the composite creates a robust seal at the wound site, effectively preventing hemorrhage during complex surgeries.
Furthermore, PANS exhibits a high lap-shear strength of up to 114.4 kPa. This strength enables the PANS-GS composite to maintain effective wet-tissue adhesion while preserving macroporosity. This preserved structure is vital because it allows for rapid blood absorption. Therefore, the device simultaneously physical seals the injury and enriches platelets, reducing reliance on fibrin-mediated pathways.
In animal studies involving rat hepatic laceration and femoral artery injury, the composite demonstrated superior efficacy. Notably, it showed significant reductions in both bleeding time and total blood loss. These improvements were consistent in both non-heparinized and systemically heparinized models. Additionally, biocompatibility tests confirmed minimal cytotoxicity and a lack of significant inflammatory response compared to standard commercial sponges.
Traditional sponges often rely on the body's natural coagulation pathway. In contrast, this new composite uses chemical cross-linking via PANS coating to ensure strong adhesion and sealing, even when coagulation is impaired.
Biocompatibility assessments indicate minimal cytotoxicity and hemolysis. Moreover, histopathological analysis suggests that it does not increase inflammatory responses compared to clinically established products.
Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or professional services. Readers should not use this information to diagnose or treat health problems or diseases. Refer to the latest local and national guidelines for clinical practice.
References

Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.


New PANS-coated gelatin sponge provides strong wet-tissue adhesion for managing hemorrhage in anticoagulant patients and visceral trauma....
5 months ago

Explore the emerging role of Brixadi, an extended-release buprenorphine injection, for managing stimulant use disorder through kappa opioid receptor antagonism and steady plasma levels.
Today

A premature neonate developed upper limb compartment syndrome after uterine rupture extruded the arm through a scar defect. Conservative management with continuous monitoring yielded complete functional recovery and normal limb growth at 10-year follow-up, highlighting non-operative safety in selected cases.
Today

Dendritic cells bridge innate and adaptive immunity in myocardial infarction. This review explores their pathological roles, circulating dynamics, novel tolerogenic interventions, and how standard cardiovascular medications modulate dendritic cells to improve post-infarction myocardial repair and patient outcomes.
Today

Endoscopic posterior cervical fusion combines minimally invasive decompression, joint preparation, and rigid screw-rod fixation for atlantoaxial pathologies. Early clinical findings demonstrate solid bony union, excellent symptom relief, and minimal soft-tissue morbidity without significant vascular compromise.
Yesterday

Atherosclerosis involves extensive glycometabolic reprogramming across immune and vascular cells. This review examines how glycolysis, the pentose phosphate pathway, and lactate-driven epigenetic shifts fuel plaque vulnerability, while highlighting novel therapeutic targets like PFKFB3 and LDHA.
Today